Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

MRC Technology Highlights Presentation of Positive Data for Lambrolizumab

Published: Wednesday, June 05, 2013
Last Updated: Wednesday, June 05, 2013
Bookmark and Share
Lambrolizumab received Therapy Designation by the U.S. FDA for the treatment of advanced melanoma.

MRC Technology has announced the presentation of positive data for lambrolizumab, initially advanced by MRC Technology’s antibody engineering group, at the American Society for Clinical Oncology meeting in Chicago.

The study is also published online in the New England Journal of Medicine.

The humanized antibody is now being developed by MSD, known as Merck in the US and Canada.

Lambrolizumab is an investigational antibody therapy targeting Programmed Death receptor (PD-1) that is currently being evaluated for the treatment of patients with advanced melanoma, and other tumor types.

MSD has recently announced that lambrolizumab has been designated as a Breakthrough Therapy for the treatment of patients with advanced melanoma by the U.S. Food and Drug Administration (FDA).

The designation of an investigational drug as a Breakthrough Therapy is intended to expedite the development and review of a candidate that is planned for use, alone or in combination, to treat a serious or life-threatening disease or condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints.

MRC Technology has humanized over 55 antibodies to date, including two marketed products, Tysabri (natalizumab) and Actemra (tocilizumab).

A further six are in clinical trials (including vedolizumab) and two more in preclinical studies.

Dave Tapolczay, CEO of MRC Technology, said: “We are delighted that our collaboration with MSD in humanizing lambrolizumab has resulted in the candidate achieving this significant status. We are hopeful that it will prove to be another significant milestone in cancer therapy and the treatment of highly invasive tumors such as advanced melanoma.”

Deepak Khanna, Managing Director of MSD UK, adds “This highlights how collaborations like this with key research institutes in the UK have the potential to really make a difference for patients across the world. We are very proud to join up with MRC Technology to work towards this future vision.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

First Treatment Approved Under EAMS
New immunotherapy (pembrolizumab) made available in the UK for treatment of adults with advanced melanoma.
Friday, March 13, 2015
Breakthrough Melanoma Treatment, Keytruda, Developed
New immunotherapy launched in the US for treatment of adults with advanced melanoma, developed using antibody humanization expertise at UK’s MRC Technology.
Friday, September 05, 2014
MRC Technology and IBP CAS Collaboration Yields Humanized Anti-CD146 Antibody
Antibody inhibits tumour angiogenesis, migration and invasion.
Wednesday, March 20, 2013
MRC Technology and AICR Partnership Reports Success for Cancer Research
MRC Technology reports first year highlights in supporting AICR’s technology transfer and IP management.
Wednesday, February 27, 2013
Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Searching Big Data Faster
Theoretical analysis could expand applications of accelerated searching in biology, other fields.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!